Clinical and Translational Radiation Oncology最新文献

{"title":"Preoperative hypofractionated radiotherapy in soft tissue sarcomas: institutional experience and clinical implications","authors":"Laura Guzmán-Gómez ,&nbsp;Cristina Morón ,&nbsp;Javier Martín-Broto ,&nbsp;Nadia Hindi ,&nbsp;José Ángel Merino-García ,&nbsp;Celia Viejo Martínez ,&nbsp;César García Mauriño ,&nbsp;Felipe López Oliva ,&nbsp;Leticia del Campo ,&nbsp;Carolina M. Cantemir-González ,&nbsp;Ignacio Azinovic","doi":"10.1016/j.ctro.2026.101112","DOIUrl":"10.1016/j.ctro.2026.101112","url":null,"abstract":"<div><h3>Background</h3><div>Conventional preoperative radiotherapy (RT) with 50 Gy in 25 fractions improves local control in soft tissue sarcomas (STS) but entails prolonged treatment and high rates of wound complications. Hypofractionated regimens may offer a shorter, more patient-convenient alternative while maintaining comparable outcomes, although they are not yet standard.</div></div><div><h3>Materials and methods</h3><div>We conducted an observational study of a prospective cohort of 24 patients with localized STS of the extremities or superficial trunk treated with preoperative hypofractionated RT between December 2021 and January 2025. Two regimens were used: moderately hypofractionated RT (MHFRT, 42.75 Gy/15 fx) and ultra-hypofractionated RT (UHFRT, 30 Gy/5 fx). Outcomes included acute toxicity, wound complications, pathological response, local control, and postoperative limb function using the Musculoskeletal Tumor Society (MSTS) and Toronto Extremity Salvage Score (TESS) scales.</div></div><div><h3>Results</h3><div>The median age was 68 years, and median tumor size 11.6 cm. All patients completed RT without interruption. A favorable pathological response (≥90% necrosis and/or ≤ 10% viable tumor) was achieved in 66.7%. Grade 1–2 dermatitis occurred in 66.7%, with no grade ≥ 3 toxicity. Major wound complications developed in 29.2%. Median MSTS and TESS scores were 26/30 (86.7%) and 88%, respectively. At 18 months median follow-up, 1- and 2-year local control rates were 100%.</div></div><div><h3>Conclusions</h3><div>Preoperative hypofractionated RT demonstrated excellent tolerance, high pathological response, and outstanding local control with acceptable wound-complication rates. Functional outcomes were favorable, supporting hypofractionated RT as a safe, efficient, and function-preserving alternative for localized STS in experienced centers. These findings provide real-world evidence supporting shorter preoperative RT schedules as a feasible and function-preserving approach in multidisciplinary sarcoma care.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"58 ","pages":"Article 101112"},"PeriodicalIF":2.7,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146071140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron deficiency in patients undergoing radiotherapy: Prevalence and clinical characteristics","authors":"Sophie Schumacher ,&nbsp;Falk Fabian ,&nbsp;Paula Lehmann ,&nbsp;Daniel Zips ,&nbsp;Felix Mehrhof ,&nbsp;Wolfram Doehner ,&nbsp;Franziska Hausmann","doi":"10.1016/j.ctro.2026.101111","DOIUrl":"10.1016/j.ctro.2026.101111","url":null,"abstract":"<div><h3>Purpose</h3><div>Anemia in patients undergoing radio-chemotherapy (RCTx) is often driven by iron deficiency and can impact quality of life and therapy outcomes. This study aimed to evaluate how RCTx affects iron metabolism and identify additional influencing factors.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study on 156 patients with cancer undergoing RCTx, primarily with head and neck cancer, brain malignancies, or metastatic disease. Anemia was defined as a HB level &lt; 13 mg/L in men and &lt; 12 mg/L in women. Iron deficiency was defined as a transferrin saturation (TSAT) below 20 %. Further blood parameters, including iron, ferritin, and transferrin, were assessed at multiple timepoints before, during, and after RCTx.</div></div><div><h3>Results</h3><div>Prevalence of anemia was 53.8% prior to treatment and increased up to 74.1% at the end of radiotherapy. At baseline, 44.2% of patients were iron deficient. Iron deficiency at baseline was associated with systemic treatment (16.5% of patients with neoadjuvant treatment), while low TSAT at end of treatment was associated with alcohol abuse. During the course of the RCTx patients with divergent changes of TSAT levels were identified (increase, decrease and no change of TSAT). Trajectory of TSAT levels was independent of oral iron substitution as nutritional supplement.</div></div><div><h3>Conclusion</h3><div>Patients undergoing radiotherapy show an exceptionally high prevalence for anemia, with iron deficiency being one of the main causes. Our study suggests that oral iron substitution may not be sufficient to treat iron deficiency in patients undergoing radiotherapy, underlining the need to enhance our understanding of iron balance and how to best target deficiencies in these patients.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101111"},"PeriodicalIF":2.7,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy","authors":"Anouk Corbeau ,&nbsp;Marij J.P. Welters ,&nbsp;Sanne Boekestijn ,&nbsp;Jan Willem M. Mens ,&nbsp;Henrike Westerveld ,&nbsp;Mila Donker ,&nbsp;Laura A. Velema ,&nbsp;Hélène van Meir ,&nbsp;Mariëtte I.E. van Poelgeest ,&nbsp;Judith R. Kroep ,&nbsp;Ingrid A. Boere ,&nbsp;Sander C. Kuipers ,&nbsp;Jeremy Godart ,&nbsp;Mischa S. Hoogeman ,&nbsp;Hein Putter ,&nbsp;Carien L. Creutzberg ,&nbsp;Remi A. Nout ,&nbsp;Sjoerd H. van der Burg ,&nbsp;Stephanie M. de Boer","doi":"10.1016/j.ctro.2026.101107","DOIUrl":"10.1016/j.ctro.2026.101107","url":null,"abstract":"<div><h3>Background</h3><div>Chemoradiotherapy is immunosuppressive in women with locally advanced cervical cancer (LACC). Both advanced external-beam radiation therapy (EBRT) and bone marrow sparing (BMS) radiotherapy techniques might lower bone marrow dose and therefore reduce the impact on the immune system. In this study, immune composition and function changes in the blood of women with LACC were evaluated for BMS volumetric-modulated arc therapy (VMAT) and exploratively compared with a historical cohort of women with LACC who underwent non-BMS radiotherapy (RT) with older EBRT techniques.</div></div><div><h3>Methods</h3><div>Women were treated with chemoradiotherapy followed by brachytherapy according to EMBRACE-II protocol (BMS VMAT) or with 46–52.5 Gy in 23–30 fractions (non-BMS RT). Blood samples for immunomonitoring were collected at set timepoints. Statistical analyses were performed using linear mixed-effects models.</div></div><div><h3>Results</h3><div>Eighteen and eleven women received BMS VMAT and non-BMS RT, respectively. Although BMS VMAT reduced mean pelvic bone dose by 8.1 Gy, it did not prevent treatment-induced leukopenia and lymphopenia. Chemoradiotherapy mainly reduced CD4+ T helper cells and B cells, leaving CD8+ T-cell and natural killer-cell frequencies untouched. T-cell reactivity to common pathogens was decreased, despite sustained T-cell proliferative capacity, and coincided with increased numbers of regulatory T cells. The potential to activate immune cells remained intact, with small increases in dendritic cells, decreases in myeloid-derived suppressor cells, and preserved capacity of myeloid cells to present antigen and activate T cells.</div></div><div><h3>Conclusion</h3><div>Our study provided insight in the dynamic immune changes following chemoradiotherapy in LACC. As immunosuppression occurred with BMS VMAT, optimizing BMS and exploring other techniques is warranted.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"58 ","pages":"Article 101107"},"PeriodicalIF":2.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146076946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging","authors":"Aisling M. Glynn ,&nbsp;Saheli Saha ,&nbsp;Ian J. Gerard ,&nbsp;Michael Velec ,&nbsp;Teodor Stanescu ,&nbsp;Juan Diaz Martinez ,&nbsp;Pablo Munoz-Schuffenegger ,&nbsp;Ali Hosni ,&nbsp;Aruz Mesci ,&nbsp;Michael Yan ,&nbsp;Cathy Rocca ,&nbsp;Andrea Shessel ,&nbsp;Tae Kyoung Kim ,&nbsp;Laura A. Dawson","doi":"10.1016/j.ctro.2026.101110","DOIUrl":"10.1016/j.ctro.2026.101110","url":null,"abstract":"<div><h3>Background</h3><div>The 1.5 T MR-Linac (MRL) provides a platform for online adaptive stereotactic body radiation therapy (SBRT). This study aims to compare gross tumor volume (GTV) on multiphasic (MP) CT and MR simulation imaging versus non-contrast MRL images and to measure changes in GTV during SBRT.</div></div><div><h3>Methods</h3><div>Primary or metastatic liver cancer patients treated with SBRT using MRL or cone beam CT (CBCT) were eligible for this prospective imaging study. At simulation, patients underwent MP CT and MP 3 T MR liver T1-weighted (T1w) imaging in exhale breath hold and T2-weighted (T2w) images on 1.5 T MRL (MRL0). Repeat MRL T2w images were acquired at each SBRT fraction. Liver tumors were contoured on simulation CT/MR and MRL0 images and on each subsequent MRL image. MRL0 GTV were compared to MP CT/MR GTV and changes during SBRT were measured.</div></div><div><h3>Results</h3><div>From August 2019 to January 2023, 29 liver tumors (23 patients) treated with SBRT, were contoured on 23 MP CT/3T MR and 103 MRL imaging datasets. Simulation MRL0 interquartile median GTV was 43.3 cc (IQR 4.3–47.7 cc), GTV on MRL0 images were smaller than MP CT/3T MR volumes by an average of 7.1 cc (95 % CI 1.9–12.2, p = 0.008) or 21.9 % (95 % CI 13.5–30.2, p = &lt;0.001). Over the course of SBRT there were no statistically significant predictable trends in tumor volume.</div></div><div><h3>Conclusion</h3><div>GTV based on MRL T2w images were significantly smaller than GTV based on MP CT/3T MR images. This systematic difference should be considered during adaptive MRL liver SBRT. There were no predictable changes in tumor volumes during SBRT.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101110"},"PeriodicalIF":2.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review","authors":"Lara Caglayan ,&nbsp;Oliver Blanck ,&nbsp;Judit Boda-Heggemann ,&nbsp;Thomas Brunner ,&nbsp;Cas Stefaan Dejonckheere ,&nbsp;Dan G. Duda ,&nbsp;Elke Firat ,&nbsp;Maria Hawkins ,&nbsp;Julian Philipp Layer ,&nbsp;Christina Leitzen ,&nbsp;Alejandra Mendez Romero ,&nbsp;Gabriele Niedermann ,&nbsp;Younèss Nour ,&nbsp;Falk Röder ,&nbsp;Gustavo Renato Sarria ,&nbsp;Davide Scafa ,&nbsp;Marta Scorsetti ,&nbsp;Shari Wiegreffe ,&nbsp;Anca-L. Grosu ,&nbsp;Eleni Gkika","doi":"10.1016/j.ctro.2026.101106","DOIUrl":"10.1016/j.ctro.2026.101106","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) represents one of the leading contributors to cancer-related deaths, with the majority of patients diagnosed at stages where curative treatment is no longer possible. Combining stereotactic body radiotherapy (SBRT) with immune checkpoint inhibition (ICI) has gained increasing attention as a therapeutic approach. Beyond its ability to provide high local tumor control (LC), SBRT can provoke immunogenic tumor cell death, promote antigen release and presentation, and modulate the tumor microenvironment in ways that enhance systemic antitumor immunity.</div><div>In this narrative review, we outline the scientific rationale for integrating SBRT with ICIs, discuss mechanistic and translational findings and summarize results from key clinical trials. The currently available data indicate a synergistic interaction, most notably reflected in improved survival and response rates. Nevertheless, variability in dose and fractionation schedules, treatment sequencing, and patient characteristics complicates interpretation. Well-designed prospective studies are needed to establish optimal protocols and identify predictive biomarkers to guide patient selection.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101106"},"PeriodicalIF":2.7,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiation of glioblastoma cells alters expression of activation and immune checkpoint molecules on type 1 and 2 dendritic cells and impacts on subsequent T cell proliferation","authors":"Celina Schuster ,&nbsp;Benjamin Frey ,&nbsp;Rainer Fietkau ,&nbsp;Stefanie Corradini ,&nbsp;Udo S. Gaipl ,&nbsp;Anja Derer","doi":"10.1016/j.ctro.2025.101102","DOIUrl":"10.1016/j.ctro.2025.101102","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Glioblastoma is the most aggressive malignant brain tumor with an overall poor prognosis despite advanced chemoradiation approaches. Immunotherapeutic strategies have not been beneficial to date. Even being present only at low level in the brain, dendritic cells (DCs) have the potential to promote anti-tumor immune responses. In this study we aimed to gain insight into the interactions between glioblastoma tumor cells, DCs and T cells to understand the molecular and cellular mechanisms driving immune alterations in glioblastoma during standard treatments for optimizing immune therapies in the future.</div></div><div><h3>Material and methods</h3><div>Impact of the conventional chemoradiation (RCT) treatment scheme of glioblastoma cells on conventional DCs type 1 and 2 (cDC) was tested in a syngeneic murine cell culture setting. GL261-luc2 glioblastoma cells were treated and subsequently co-cultured with cDC1-like and cDC2-like cells. Their immunological status was determined as follows: Expression of activation and immune checkpoint markers was quantified via flow cytometry. Cytokine and chemokine secretion was measured by bead-based immunoassays. Mixed lymphocyte reactions with either CD4+ or CD8+ T cells were performed to determine the potential of cDCs in stimulating T cell proliferation.</div></div><div><h3>Results</h3><div>The cellular contact of cDC1-like cells with RCT-treated glioblastoma cells shifted their immune phenotype to a more activated one, whereas the activation of cDC2-like cells was limited. Furthermore, the extracellular profile of inflammatory and immunoregulatory cytokines and chemokines was highly dependent on the tumor cell treatment scheme in co-culture with cDC1-like cells, with the most pronounced effect after RCT. These modifications in the activation status of cDC1- and cDC2-like cells after tumor cell contact subsequently resulted in significantly enhanced CD8⁺ and CD4⁺ T cell proliferation.</div></div><div><h3>Conclusion</h3><div>Current glioblastoma cell treatment impacts on the subsequent activation of cDCs and T cells and should serve as basis for improving immunotherapeutic strategies of brain tumors.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101102"},"PeriodicalIF":2.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative oesophageal dose and risk of high-grade toxicity in thoracic re-irradiation: a dose/toxicity analysis","authors":"Robert Rulach ,&nbsp;Stephen Harrow ,&nbsp;Anthony J. Chalmers ,&nbsp;John Fenwick","doi":"10.1016/j.ctro.2026.101108","DOIUrl":"10.1016/j.ctro.2026.101108","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Re-irradiation (re-RT) in recurrent thoracic cancer is being performed more often and can cause severe toxicity. Information is lacking on safe re-irradiation dose constraints. We modelled the relationship between cumulative oesophageal dose and grade 3 or worse (≥G3) oesophageal toxicity to develop<!--> <!-->dose constraints.</div></div><div><h3>Materials and methods</h3><div>We performed a literature search for reports of thoracic re-RT and selected studies that quoted cumulative oesophageal maximum dose (cD_max) in equivalent dose in 2 Gy fractions (EQD2) and ≥G3 toxicity. Additional collected data were<!--> <!-->inter-treatment interval and concurrent chemotherapy use (conCT) at re-irradiation. Logistic regression analyses were performed. The models were used to predict the cD_max <!-->associated with a 5%<!--> <!-->≥G3 toxicity rate. Model performance was assessed using the Pearson correlation coefficient (PCC).</div></div><div><h3>Results</h3><div>We identified 21 studies (505 patients), with 49 ≥G3 toxic events. The median oesophageal cD_max <!-->and interval were 84.8 Gy₃ <!-->(3.7 – 220.6 Gy₃ <!-->EQD2) and 15.5 months (1–162) respectively. Use of conCT and oesophageal cD_max <!-->were significantly associated with toxicity on univariable and multivariable modelling (both p &lt; 0.001). The maximum likelihood doses associated with 5% risk of ≥G3 toxicity with/without chemotherapy were cD_max <!-->43.0 Gy₃ <!-->(95% CI: −18.5, 108.8) and 94.2 Gy₃ <!-->(95% CI: 79.6, 142.8) respectively. The model had a PCC of 0.75 (p = 0.013) suggesting good correlation to the dataset.</div></div><div><h3>Conclusion</h3><div>The models predict a 5% toxicity<!--> <!-->at cD_max <!-->43.0 Gy₃ <!-->and 94.2 Gy₃ <!-->EQD2 with/without chemotherapy. This<!--> <!-->supports a cD_max <!-->constraint of &lt;95 Gy₃ <!-->EQD2 to limit ≥G3 toxicity to under 5%,<!--> <!-->consistent with the<!--> <!-->American Radium Society constraints (&lt;100 Gy₃ <!-->EQD2). ConCT with re-irradiation has a large radiosensitising effect.<!--> <!-->Limitations of this study include the use of old, retrospective data resulting in<!--> <!-->wide CIs around the<!--> <!-->predictions and insufficient data to<!--> <!-->predict a volumetric constraint. Further modelling with more detailed dose data is required to refine and validate these predictions.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101108"},"PeriodicalIF":2.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal conservative local treatment based on combined brachytherapy and external beam radiation therapy for paediatric pelvic and perineal rhabdomyosarcoma","authors":"Xavier Musset ,&nbsp;Sophie Espenel ,&nbsp;Jeanne Riverain ,&nbsp;Elaine Limkin ,&nbsp;Florent Guerin ,&nbsp;Véronique Minard ,&nbsp;Isabelle Dumas ,&nbsp;Noura Sellami ,&nbsp;Valentine Martin ,&nbsp;Stéphanie Bolle ,&nbsp;Mario Terlizzi","doi":"10.1016/j.ctro.2025.101104","DOIUrl":"10.1016/j.ctro.2025.101104","url":null,"abstract":"<div><h3>Purpose</h3><div>In pediatric pelvic or perineal rhabdomyosarcoma, organ preservation rates are high following neoadjuvant chemotherapy. We assessed the impact of combining external beam radiation therapy (EBRT) and brachytherapy (BT) on local control and functional outcomes.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed records of all children who received both EBRT and a BT boost in our department from 2005 to 2023. Data collected included tumor relapse, local control, survival and late toxicity rates. Treatment was administered as part of a multimodal conservative radio-surgical approach.</div></div><div><h3>Results</h3><div>Eighteen patients were identified, with a median age of 4 years (range, 2.9 – 8.6 years). According to the Intergroup Rhabdomyosarcoma Study (IRS) risk groups, 10 patients were classified as IRS-III and 8 as IRS-IV. Seven patients had metastases at diagnosis. The median number of chemotherapy cycles prior to local treatment was 8 (range, 5–10). Nine patients (50 %) underwent prior conservative surgery, followed by radiation therapy consisting of both BT and EBRT. This combination was indicated for at least one the following reasons: nodal invasion (n = 11, 61 %), risk of peritoneal dissemination (n = 3, 17 %) and/or local extension (n = 7, 39 %). The median prescribed dose was 20 Gy (range 12–30 Gy) for BT and 50.4 Gy (range, 18.8–55 Gy) for EBRT. Two patients were treated with HDR BT, while the remaining received LDR (n = 4) or PDR (n = 12).The median follow-up period was 4.6 years (range, 2.9–6.6 years). At the last follow-up, failure free-survival was 67 %, local control was 78 % and overall survival was 83 %. Four patients experienced grade II late urinary toxicities, including dysuria or incontinence in two patients. One patient required secondary cystectomy, and another received botulinum toxin injections in the bladder neck.</div></div><div><h3>Conclusion</h3><div>Organ preservation with favorable functional outcome can be achieved in pelvic and perineal rhabdomyosarcoma by combining BT and EBRT, with or without prior surgery. This approach requires close collaboration to develop customized radiation therapy plans. Extended follow-up is necessary to assess long-term functional outcomes.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101104"},"PeriodicalIF":2.7,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vestibular dose predicts toxicity in stereotactic radiosurgery for vestibular schwannomas","authors":"Dimitrios Daskalou ,&nbsp;Edouard Romano ,&nbsp;Sophie Neveü ,&nbsp;Pelagia Tsoutsou ,&nbsp;Nikolaos Koutsouvelis ,&nbsp;Francis Rousset ,&nbsp;Nils Guinand ,&nbsp;Minerva Becker ,&nbsp;Pascal Senn ,&nbsp;Sebastien Tran","doi":"10.1016/j.ctro.2025.101105","DOIUrl":"10.1016/j.ctro.2025.101105","url":null,"abstract":"<div><h3>Introduction</h3><div>Stereotactic radiosurgery (SRS) provides excellent tumor control in small and medium vestibular schwannomas (VS), but its impact on the vestibular system remains uncertain. This study examines the effects of SRS on subjective vestibular symptoms, vestibular function, and potential predictors of symptom worsening.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on adult VS patients treated with SRS over eight years. Vestibular symptoms were graded at baseline and six months post-SRS. The vestibular sensory organs (VSO) were defined as the combined volume of the saccule, utricle, and ampullae. Vestibular function was assessed with bithermal, bilateral caloric testing, video head impulse testing, and vestibular evoked myogenic potentials. Two illustrative treatment plans were generated to assess feasibility of vestibular dose reduction without compromising planning target volume (PTV) or cochlear constraints.</div></div><div><h3>Results</h3><div>Among 45 VS patients (median age 61.4 years), 14 (31 %) reported worsened vestibular symptoms at six months. These patients had higher Dose_mean to VSO (6.45 Gy vs 2.92 Gy, p &lt; 0.0001). A Dose_mean &gt; 4 Gy was strongly associated with symptom worsening (OR = 27.3, 95 % CI [3.4–301.8], p = 0.0002). Similar associations were observed for Dose_max, with an 8 Gy threshold. Higher Dose_mean to the lateral ampulla was correlated with a greater percentage change in caloric weakness (slope = 7.77, R² = 0.38, p = 0.04). In two illustrative plans, VSO optimisation lowered vestibular dose without compromising PTV coverage or cochlear dose.</div></div><div><h3>Conclusion</h3><div>Higher vestibular radiation dose is strongly associated with worsened vestibular symptoms and possibly with functional decline. Dose reduction to vestibular subunits is feasible without compromising the tumor dose, helping mitigate these effects.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101105"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-GRID enhances survival and reduces toxicity in an orthotopic murine model of oral squamous cell carcinoma: A proof-of-concept study","authors":"Loris Roncali ,&nbsp;Maria Isabel Acuña-Perez ,&nbsp;Julie Espenon ,&nbsp;Manuel Sánchez-García ,&nbsp;Victor Luna-Vega ,&nbsp;Eva G. Kölmel ,&nbsp;Cristèle Gilbert ,&nbsp;Mathieu Sertorio ,&nbsp;Marjorie Juchaux ,&nbsp;Yolanda Prezado","doi":"10.1016/j.ctro.2025.101101","DOIUrl":"10.1016/j.ctro.2025.101101","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Oral squamous cell carcinoma (OSCC) remains a major clinical challenge, with limited therapeutic options and poor outcomes. Among the emerging approaches to address this unmet need, spatially fractionated radiotherapy (SFRT) using mini-GRID patterns has emerged as a promising approach, delivering high radiation doses through narrowly collimated beamlets that spare intervening normal tissue and may enhance the therapeutic index. This study evaluated the efficacy and safety of mini-GRID RT in an orthotopic, syngeneic murine model of OSCC.</div></div><div><h3>Materials and methods</h3><div>C57BL/6 mice bearing MOC1 tumors were randomized to receive conventional radiotherapy (conv-RT; 20 Gy), mini-GRID RT (20 Gy average dose), or no treatment. Endpoints included survival, tumor growth, body weight, and histopathological assessment of tumor and surrounding normal tissues.</div></div><div><h3>Results</h3><div>Mini-GRID RT significantly extended median survival (56 days) compared with controls (36 days; <em>p</em> = 0.0456) and conv-RT (35 days; <em>p</em> = 0.0181). Tumor growth was delayed by approximately 20 days in the mini-GRID group, with long-term survivors regaining baseline body weight within 15 days post-irradiation. Fewer animals in the mini-GRID group required early euthanasia due to acute toxicity compared with the conv-RT group. Histological examination revealed no significant increase in normal tissue damage in mini-GRID-treated mice relative to conv-RT.</div></div><div><h3>Conclusion</h3><div>These findings indicate that mini-GRID RT can improve survival while maintaining a favorable toxicity profile in OSCC, supporting its potential as a novel high-dose radiotherapy approach. Further studies are warranted to elucidate underlying mechanisms, including vascular and immune-mediated responses, and to assess its translational relevance in clinical practice.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101101"},"PeriodicalIF":2.7,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145880919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}